Azurity engaged Brandsymbol to evaluate up to 10 creative name candidates for their sitagliptin oral solution through a comprehensive Risk Assessment. Our analysis prioritized a shortlist of names for FDA submission, culminating in the proprietary name submission report for the selected name. The result? BRYNOVIN was approved by the FDA on January 16, reinforcing Brandsymbol’s commitment to delivering regulatory-ready solution.